Proactive’s Post

Creo Medical Group PLC (AIM:CREO)'s Speedboat technology is significantly reducing costs and improving patient outcomes in minimally invasive surgeries, according to recent NHS Supply Chain data. Analysing 130 Speedboat submucosal dissection (SSD) procedures at East Kent University Hospitals Foundation Trust, the report highlighted remarkable reductions in hospital stays and critical care costs compared to traditional surgical methods. Specifically, it revealed an 87% decrease in the average length of hospital stays, from 8.39 days down to just 1.07 days, and a 99% reduction in critical care costs. Accommodation costs per patient also saw a drop of 91%, from £3,400 to £300, while admission costs were cut by 62%. Over one year, overall costs per patient fell by 59%, from £8,800 to £3,600. Additionally, the costs associated with theatre procedures were reduced by 38%. More at #Proactive #ProactiveInvestors #creomedical #speedboattechnology http://ow.ly/S7ET105qBv0

Creo Medical technology leads to significant efficiencies, NHS case study finds

Creo Medical technology leads to significant efficiencies, NHS case study finds

proactiveinvestors.co.uk

To view or add a comment, sign in

Explore topics